miR-3150b-3p Promotes Vascular Smooth Muscle Cell Injury by Targeting ARL5B.

BackgroundCoronary heart disease (CHD) has a relatively high mortality rate. This study aims to explore the expression level of miR-3150b-3p in CHD and its potential mechanisms of action.MethodThis study collected basic information from 120 hypertensive patients and 110 CHD patients. Serum levels of miR-3150b-3p were quantified using qRT-PCR. The diagnostic value of miR-3150b-3p was evaluated through the ROC curve, and Pearson analysis tested its correlation with CHD severity. In vitro, ox-LDL was used to induce HVSMCs. Cell viability was assessed using the CCK-8 assay, inflammatory factors were measured by ELISA, and oxidative stress levels were evaluated by detecting superoxide dismutase activity and malondialdehyde content. miR-3150b-3p-ARL5B interaction was verified by luciferase assay and RIP.ResultsSerum miR-3150b-3p is up-regulated in CHD patients, correlates with disease severity. ROC curve demonstrated that miR-3150b-3p has robust diagnostic value. In vitro experiments demonstrated that the miR-3150b-3p inhibitor significantly reduced ox-LDL-induced inflammatory factors, increased SOD activity, and decreased MDA content. In addition, miR-3150b-3p was verified to target ARL5B.ConclusionsThe level of miR-3150b-3p in the serum of CHD patients is significantly elevated and positively correlated with disease-related indicators of CHD. miR-3150b-3p can regulate cellular functions and targetARL5B, providing a new potential target for the early diagnosis and treatment of CHD.